Amylyx Pharmaceuticals Inc (AMLX) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Over the past 3 years, Amylyx Pharmaceuticals Inc has achieved a revenue compound annual growth rate (CAGR) of 574.3%, while earnings have grown at 50.8% CAGR.
Historical revenue and profitability trends for Amylyx Pharmaceuticals Inc
The chart above illustrates Amylyx Pharmaceuticals Inc's revenue trajectory over the past 3 years. The revenue pattern shows the challenges the company has faced in recent periods.
Annual percentage change in revenue and earnings
Growth rates provide insight into the momentum of Amylyx Pharmaceuticals Inc's business.
How efficiently Amylyx Pharmaceuticals Inc converts revenue into profit
Profit margins reveal how much of each dollar of revenue Amylyx Pharmaceuticals Inc retains at different stages:
Analyst estimates and forward-looking indicators
Wall Street analysts project Amylyx Pharmaceuticals Inc to continue growing earnings in the coming year. The consensus analyst rating is 4.5714 based on 7 analysts.
Based on our comprehensive analysis, Amylyx Pharmaceuticals Inc (AMLX) demonstrates declining growth characteristics.
This growth analysis provides a comprehensive view of Amylyx Pharmaceuticals Inc's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.
See how Amylyx Pharmaceuticals Inc stacks up against similar companies
Explore growth analysis for top stocks
Related: AMLX Valuation, AMLX Dividend, AMLX Financial Health
Compare: AMLX vs AAPL, AMLX vs MSFT, AMLX vs GOOGL